ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2018
Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Criteria for Hyponatremic Overcorrection: Systematic Review and Cohort Study of Emergently Ill Patients.Journal of general internal medicine · 2020Pooled it
- Serum Copeptin Rises After Tolvaptan for Hyponatraemia, but Does Not Predict Risk of Rapid Sodium Rise: Pre-Specified Secondary Analysis of the TVFR Trial.Clinical endocrinology · 2026Trial
- A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.Journal of the American Society of Nephrology : JASN · 2020Trial
- Association between kidney function and risk of hyponatremia: a single-center, cross-sectional study in the outpatient setting.Clinical and experimental nephrology · 2026Article
- Furosemide plus oral sodium chloride for syndrome of inappropriate antidiuresis after fluid restriction failure.Clinical kidney journal · 2026Article
- Acute Autonomic Sensory Neuropathy Causing Severe Hyponatremia: A Rare Cause of Syndrome of Inappropriate Antidiuresis.JCEM case reports · 2026Article
- Syndrome of Inappropriate Antidiuresis.Journal of the American Society of Nephrology : JASN · 2025Review
- Clinical factors associated with hyponatremia correction during treatment with oral urea.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- Case report: Persistent syndrome of inappropriate antidiuresis after traumatic brain injury: spontaneous resolution and impact on RAAS and bone metabolism over five years.Frontiers in endocrinology · 2024Article
- Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management.Endocrine reviews · 2023Review
- Safety and Efficacy of Vaptans in the Treatment of Hyponatremia from Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review.Journal of clinical medicine · 2023Review
- Clinical Approach to Euvolemic Hyponatremia.Cureus · 2023Review
- Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD).Therapeutic advances in endocrinology and metabolism · 2023Review
- Disorders of Salt and Water Balance After Pituitary Surgery.The Journal of clinical endocrinology and metabolism · 2022Article
- Survival analysis in cancer patients with hyponatremia: effectiveness of tolvaptan treatment.International urology and nephrology · 2022Article
- Approach to the Patient: Hyponatremia and the Syndrome of Inappropriate Antidiuresis (SIAD).The Journal of clinical endocrinology and metabolism · 2022Review
- Clinical efficacy of urea treatment in syndrome of inappropriate antidiuretic hormone secretion.Scientific reports · 2022Article
- The management and outcome of hyponatraemia following transsphenoidal surgery: a retrospective observational study.Acta neurochirurgica · 2022Observational
- The management of acute and chronic hyponatraemia.Therapeutic advances in endocrinology and metabolism · 2022Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundTolvaptan effectively corrects hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), but undesired overcorrection can occur. We hypothesized that pretherapy parameters can predict the rapidity of response to tolvaptan in SIADH. STUDY
designMulticenter historical cohort study. SETTING &
participantsAdults with SIADH or congestive heart failure (CHF) treated with tolvaptan for a serum sodium concentration ≤ 130 mEq/L at 5 US hospitals. PREDICTORS: Demographic and laboratory parameters. OUTCOMES: Rate of change in serum sodium concentration. MEASUREMENTS: Spearman correlations, analysis of variance, and multivariable linear mixed-effects models.
results28 patients with SIADH and 39 patients with CHF treated with tolvaptan (mean baseline serum sodium, 120.6 and 122.4 mEq/L, respectively) were studied. Correction of serum sodium concentration > 12 mEq/L/d occurred in 25% of patients with SIADH compared to 3% of those with CHF (P<0.001). Among patients with SIADH, the increase in serum sodium over 24 hours was correlated with baseline serum sodium concentration (r=-0.78; P<0.001), serum urea nitrogen concentration (SUN; r=-0.76; P<0.001), and estimated glomerular filtration rate (r=0.58; P=0.01). Baseline serum sodium and SUN concentrations were identified as independent predictors of change in serum sodium concentration in multivariable analyses. When patients were grouped into 4 categories according to baseline serum sodium and SUN median values, those with both low baseline serum sodium (≤121 mEq/L) and low baseline SUN concentrations (≤10mg/dL) exhibited a significantly greater rate of increase in serum sodium concentration (mean 24-hour increase of 15.4 mEq/L) than the other 3 categories (P<0.05). Among patients with CHF, only baseline SUN concentration was identified as an independent predictor of change in serum sodium concentration over time. LIMITATIONS: Lack of uniformity in serial serum sodium concentration determinations and documentation of water intake.
conclusionsBaseline serum sodium and SUN values are predictive of the rapidity of hyponatremia correction following tolvaptan use in SIADH. We advise caution when dosing tolvaptan in patients with both low serum sodium and SUN concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.